Theriva Biologics, Inc.
TOVX
$1.42
$0.00780.55%
AMEX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -12.01% | -1.55% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.21% | -5.24% | |||
| Operating Income | 1.21% | 5.24% | |||
| Income Before Tax | 42.44% | 7.09% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 42.44% | 7.09% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 42.44% | 7.09% | |||
| EBIT | 1.21% | 5.24% | |||
| EBITDA | 1.09% | 5.18% | |||
| EPS Basic | 76.62% | 36.47% | |||
| Normalized Basic EPS | 59.63% | 35.17% | |||
| EPS Diluted | 76.62% | 36.47% | |||
| Normalized Diluted EPS | 59.63% | 35.17% | |||
| Average Basic Shares Outstanding | 146.20% | 46.24% | |||
| Average Diluted Shares Outstanding | 146.20% | 46.24% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||